Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.48 |
| ▸ | DPP4 | P27487 | 2/20 | 0.35 |
| ▸ | FAP | Q12884 | 1/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.35 |
| ▸ | LAP3 | P28838 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.31 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.31 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7367150 | 0.84 | SLC7A5 (0.36) | SLC7A5DPP4DPP7TSHRSLC1A3 | |
| SCHEMBL769572 | 0.84 | SLC7A5 (0.48) | SLC7A5DPP4FAPDPP8DPP9 | |
| SCHEMBL769573 | 0.84 | SLC7A5 (0.48) | SLC7A5DPP4FAPDPP8DPP9 | |
| SCHEMBL84795 | 0.84 | SLC7A5 (0.48) | SLC7A5DPP4FAPDPP8DPP9 | |
| Hydrochloric Acid SCHEMBL1456828 | 0.82 | SLC7A5 (0.46) | SLC7A5DPP4FAPDPP8DPP9 | |
| SCHEMBL4762689 | 0.82 | SLC7A5 (0.46) | SLC7A5DPP4FAPDPP8DPP9 | |
| Hydrochloric Acid SCHEMBL17099133 | 0.82 | SLC7A5 (0.46) | SLC7A5DPP4FAPDPP8DPP9 | |
| SCHEMBL15566190 | 0.82 | SLC7A5 (0.46) | SLC7A5DPP4FAPDPP8DPP9 | |
| SCHEMBL2785568 | 0.80 | SLC7A5 (0.55) | SLC7A5DPP4FAPDPP8DPP9 | |
| SCHEMBL25145019 | 0.80 | SLC7A5 (0.44) | SLC7A5DPP4FAPDPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362065-B2 | Carbazole carboxamide compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-29 | — | — | US | disclosed |
| US-20120058996-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058996-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, FLT3, JAK1 | SLC7A5 2636/4885DPP4 1809/4885FAP 4438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.